A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

Deepak L Bhatt; Keith A Fox; Werner Hacke; Peter B Berger; Henry R Black; William E Boden; Patrice Cacoub; Eric A Cohen; Mark A Creager; J Donald Easton; Marcus D Flather; Steven M Haffner; Christian W Hamm; Graeme J Hankey; S Claiborne Johnston; Koon-Hou Mak; Jean-Louis Mas; Gilles Montalescot; Thomas A Pearson; P Gabriel Steg; Steven R Steinhubl; Michael A Weber; Joan Booth; Eric J Topol; CHARISMA Investigators

doi:10.1016/j.ahj.2005.03.017

A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

Deepak L Bhatt, Keith A Fox, Werner Hacke, Peter B Berger, Henry R Black, William E Boden, Patrice Cacoub, Eric A Cohen, Mark A Creager, J Donald Easton, Marcus D Flather, Steven M Haffner, Christian W Hamm, Graeme J Hankey, S Claiborne Johnston, Koon-Hou Mak, Jean-Louis Mas, Gilles Montalescot, Thomas A Pearson, P Gabriel StegSteven R Steinhubl, Michael A Weber, Joan Booth, Eric J Topol, CHARISMA Investigators

Research output: Contribution to journal › Article › peer-review

37 Citations (Scopus)

Abstract

The manifestations of atherothrombosis such as myocardial infarction, ischemic stroke, limb ischemia, or cardiovascular death pose a global health care burden. Additional therapies to decrease ischemic events in patients with established vascular disease or at risk for developing vascular disease are necessary. We sought to characterize the risk factors and treatments of a diverse contemporary population of patients with atherothrombosis.

Original language	English
Pages (from-to)	401.e1
Journal	American Heart Journal
Volume	150
Issue number	3
DOIs	https://doi.org/10.1016/j.ahj.2005.03.017
Publication status	Published - Sep 2005

Keywords

Adult
Aged
Aged, 80 and over
Brain Ischemia
Cardiovascular Diseases
Coronary Disease
Female
Humans
Ischemia
Leg
Male
Middle Aged
Myocardial Infarction
Risk Factors
Ticlopidine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ahj.2005.03.017

Cite this

Bhatt, D. L., Fox, K. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., Flather, M. D., Haffner, S. M., Hamm, C. W., Hankey, G. J., Johnston, S. C., Mak, K-H., Mas, J-L., Montalescot, G., Pearson, T. A., ... CHARISMA Investigators (2005). A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American Heart Journal, 150(3), 401.e1. https://doi.org/10.1016/j.ahj.2005.03.017

@article{f259f64004214bdcb42f5942d8a1da82,

title = "A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial",

abstract = "The manifestations of atherothrombosis such as myocardial infarction, ischemic stroke, limb ischemia, or cardiovascular death pose a global health care burden. Additional therapies to decrease ischemic events in patients with established vascular disease or at risk for developing vascular disease are necessary. We sought to characterize the risk factors and treatments of a diverse contemporary population of patients with atherothrombosis.",

keywords = "Adult, Aged, Aged, 80 and over, Brain Ischemia, Cardiovascular Diseases, Coronary Disease, Female, Humans, Ischemia, Leg, Male, Middle Aged, Myocardial Infarction, Risk Factors, Ticlopidine",

author = "Bhatt, {Deepak L} and Fox, {Keith A} and Werner Hacke and Berger, {Peter B} and Black, {Henry R} and Boden, {William E} and Patrice Cacoub and Cohen, {Eric A} and Creager, {Mark A} and Easton, {J Donald} and Flather, {Marcus D} and Haffner, {Steven M} and Hamm, {Christian W} and Hankey, {Graeme J} and Johnston, {S Claiborne} and Koon-Hou Mak and Jean-Louis Mas and Gilles Montalescot and Pearson, {Thomas A} and Steg, {P Gabriel} and Steinhubl, {Steven R} and Weber, {Michael A} and Joan Booth and Topol, {Eric J} and {CHARISMA Investigators}",

year = "2005",

month = sep,

doi = "10.1016/j.ahj.2005.03.017",

language = "English",

volume = "150",

pages = "401.e1",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Mosby Inc.",

number = "3",

}

Bhatt, DL, Fox, KA, Hacke, W, Berger, PB, Black, HR, Boden, WE, Cacoub, P, Cohen, EA, Creager, MA, Easton, JD, Flather, MD, Haffner, SM, Hamm, CW, Hankey, GJ, Johnston, SC, Mak, K-H, Mas, J-L, Montalescot, G, Pearson, TA, Steg, PG, Steinhubl, SR, Weber, MA, Booth, J, Topol, EJ & CHARISMA Investigators 2005, 'A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial', American Heart Journal, vol. 150, no. 3, pp. 401.e1. https://doi.org/10.1016/j.ahj.2005.03.017

TY - JOUR

T1 - A global view of atherothrombosis

T2 - baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

AU - Bhatt, Deepak L

AU - Fox, Keith A

AU - Hacke, Werner

AU - Berger, Peter B

AU - Black, Henry R

AU - Boden, William E

AU - Cacoub, Patrice

AU - Cohen, Eric A

AU - Creager, Mark A

AU - Easton, J Donald

AU - Flather, Marcus D

AU - Haffner, Steven M

AU - Hamm, Christian W

AU - Hankey, Graeme J

AU - Johnston, S Claiborne

AU - Mak, Koon-Hou

AU - Mas, Jean-Louis

AU - Montalescot, Gilles

AU - Pearson, Thomas A

AU - Steg, P Gabriel

AU - Steinhubl, Steven R

AU - Weber, Michael A

AU - Booth, Joan

AU - Topol, Eric J

AU - CHARISMA Investigators

PY - 2005/9

Y1 - 2005/9

N2 - The manifestations of atherothrombosis such as myocardial infarction, ischemic stroke, limb ischemia, or cardiovascular death pose a global health care burden. Additional therapies to decrease ischemic events in patients with established vascular disease or at risk for developing vascular disease are necessary. We sought to characterize the risk factors and treatments of a diverse contemporary population of patients with atherothrombosis.

AB - The manifestations of atherothrombosis such as myocardial infarction, ischemic stroke, limb ischemia, or cardiovascular death pose a global health care burden. Additional therapies to decrease ischemic events in patients with established vascular disease or at risk for developing vascular disease are necessary. We sought to characterize the risk factors and treatments of a diverse contemporary population of patients with atherothrombosis.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Brain Ischemia

KW - Cardiovascular Diseases

KW - Coronary Disease

KW - Female

KW - Humans

KW - Ischemia

KW - Leg

KW - Male

KW - Middle Aged

KW - Myocardial Infarction

KW - Risk Factors

KW - Ticlopidine

U2 - 10.1016/j.ahj.2005.03.017

DO - 10.1016/j.ahj.2005.03.017

M3 - Article

C2 - 16169314

VL - 150

SP - 401.e1

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3

ER -